Alcresta Therapeutics Announces Enrollment of First Patient in Clinical Trial Evaluating Use of RELiZORB in Pancreatitis Patients at Massachusetts General Hospital
WALTHAM, Mass., April 29, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that Massachusetts General Hospital (MGH) has enrolled the first patient in an investigator-initiated trial evaluating the efficacy of RELiZORB in managing exocrine pancreatic insufficiency (EPI) in tube-fed pancreatitis patients.
'We are excited about the enrollment of the first patient in this study to evaluate the potential benefits of RELiZORB use in tube-fed pancreatitis patients. Acute pancreatitis is one of the leading gastrointestinal causes of hospital admissions, and there is a growing focus on managing long-term complications of pancreatitis, which includes EPI,' said Casey Luckhurst, MD, Pancreatic and General Surgeon and Inpatient Director of Massachusetts General Hospital's Pancreatitis Treatment Center.
Fat malabsorption is often associated with EPI conditions including pancreatitis, cystic fibrosis, and gastrointestinal cancers and can result in weight loss and serious gastrointestinal symptoms. For patients with fat malabsorption who require tube feeding, RELiZORB is the only FDA-cleared enzyme device designed to mimic the function of pancreatic lipase to improve absorption of fats for tube-fed patients. Studies have demonstrated that RELiZORB is safe, well-tolerated, and effective in improving fat absorption for patients with cystic fibrosis.
'The initiation of study recruitment marks an important step toward expanding the body of clinical evidence that supports RELiZORB use in Alcresta's target therapeutic areas,' said Michael Yeh, MD, Senior Vice President of Medical Affairs at Alcresta Therapeutics. 'This is one of four clinical trials evaluating the safety and efficacy of RELiZORB in malabsorptive conditions supporting our mission to improve nutritional care and outcomes for tube-fed patients living with rare diseases.'
For more information about RELiZORB clinical trials, visit ClinicalTrials.gov:
About RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE
RELiZORB is a first-of-its-kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase and is indicated for use in pediatric patients (ages 1 year and above) and adult patients to hydrolyze fats in enteral formula. RELiZORB was developed using Alcresta's proprietary enzyme immobilization technology, iLipase®, which is the digestive enzyme lipase bound to small polymeric bead carriers. RELiZORB connects in-line to enteral feeding systems. As enteral formula passes through RELiZORB, the bound lipase breaks down formula fats into an absorbable form prior to ingestion. RELiZORB was FDA-cleared in 2015 for use in adult patients and was cleared in 2017 for use in children as young as five years old. Use was expanded to pediatric patients as young as two years old in August 2023 and expanded again for patients as young as one year old in January 2025. The next-generation RELiZORB device was introduced to market in May 2024 with broader formula compatibility, an increase in the number of devices used per day and use in both continuous and bolus-feeding set ups.
About Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Alcresta currently markets RELiZORB for enterally-fed patients with pancreatic insufficiency, which occurs in cystic fibrosis, pancreatic cancer, and pancreatitis, and short bowel syndrome, which is marked by significant malabsorption due to limited absorptive area as a result of resection. Alcresta is currently developing a platform application for prematurely born infants treated in the NICU. Alcresta Therapeutics, Inc. is backed by Linden Capital Partners and HealthQuest Capital. More information can be found at www.alcresta.com.
Internal Media Contact:
Natalie Bronfin
Alcresta Therapeutics, Inc.
[email protected]
617-431-3600
View original content: https://www.prnewswire.com/news-releases/alcresta-therapeutics-announces-enrollment-of-first-patient-in-clinical-trial-evaluating-use-of-relizorb-in-pancreatitis-patients-at-massachusetts-general-hospital-302440918.html
SOURCE Alcresta Therapeutics, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide. Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages. Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio. America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients. "We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines." Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients." "As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter. "Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete," Rep. Carey said. Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans. Contacts : Hikma Pharmaceuticals PLC Investors Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050 Media Steven Weiss US Communications +1 732 788 8279 About Hikma(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: View original content to download multimedia: SOURCE Hikma Pharmaceuticals USA Inc.
Yahoo
6 hours ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool
